Bio-Rad Laboratories, Inc. (BIO) Guidance & Earnings Results
On 2026-08-04 Bio-Rad Laboratories, Inc. reaffirmed guidance: "FY2026 non-GAAP currency-neutral revenue: -3.0% to +0.5%; non-GAAP operating margin:…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BIOBio-Rad Laboratories, Inc.Follow BIO — free
—
Price chart with a free account
- Market cap
- 9.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 4 Aug 26 | Reaffirmed | FY2026 non-GAAP currency-neutral revenue: -3.0% to +0.5%; non-GAAP operating margin: 10.0-12.0% · full year |
| 30 Apr 26 | Lowered | Revenue growth cut from +0.5-1.5% to -3.0% to +0.5%; operating margin cut from 12-12.5% to 10-12% · full year |
| 29 Oct 25 | Reaffirmed | Non-GAAP currency-neutral revenue growth 0-1%; non-GAAP operating margin 12-13%. · full year |
| 31 Jul 25 | Raised | FY25 non-GAAP currency-neutral revenue growth ~0-1.0% (prior ~-1% to +1.5%); non-GAAP operating margin ~12-13% (prior ~10-12%) · full year |
Bio-Rad Laboratories, Inc. — questions
- What guidance did Bio-Rad Laboratories, Inc. give?
- On 2026-08-04: "FY2026 non-GAAP currency-neutral revenue: -3.0% to +0.5%; non-GAAP operating margin: 10.0-12.0%"
- When does Bio-Rad Laboratories, Inc. report earnings?
- Bio-Rad Laboratories, Inc.'s next earnings report is expected on 2026-11-04.
Every figure on this page comes from Bio-Rad Laboratories, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.